Table 2 Echocardiography, biomarkers and clinical outcome in all patients and stratified by the presence of LV systolic function
All patients | LV systolic function | P value | ||
|---|---|---|---|---|
n = 74 | Normal n = 38 | Abnormal n = 15 | ||
Echocardiography Left ventricle | ||||
LVEF, % | 62 (53–67.5) | 64 (59–69.5) | 47 (39–55) | <0.001 |
LVEF < 50% | 8 (13.6%) | 0 (0%) | 8 (53.5%) | <0.001 |
LV s’, cm/sec | 6 (5–7) | 6 (6–8) | 4 (4–5) | <0.001 |
MAPSE, mm | 11 (9–13) | 11 (11–14) | 7 (6–9) | <0.001 |
GLS | −17 (−21 to −15) | −20 (−22 to −17) | −13 (−14 to −10) | < 0.001 |
VTI, cm | 18.7 (15.4 to 21.9) | 19.4 (16.4 to 22.5) | 17 (11.6 to 21.7) | 0.177 |
Right ventricle | ||||
TAPSE, mm | 18 (16 to 22) | 20.5 (18 to 23) | 15 (12 to 17) | < 0.001 |
FAC, % | 46 (39 to 53) | 46 (41 to 54) | 42 (33 to 48.5) | 0.117 |
RVEDA:LVEDA | 0.53 (0.46 to 0.57) | 0.54 (0.46 to 0.57) | 0.52 (0.45 to 0.57) | 0.664 |
RV FWS | −23 (−27 to −21) | −25 (−29 to −21) | −23 (−25 to −16) | 0.111 |
RV TV s’, cm/sec | 10 (8 to 12) | 11 (9 to 12) | 7(6 to 9) | 0.005 |
hsTnT max, ng/l | 53 (21 to 127) | 43 (16 to 105) | 126 (50 to 284) | 0.006 |
AMInj | 60 (82%) | 30 (78.9%) | 14 (93.3%) | 0.418 |
Vasopressor days | 9.5 (5 to 21.25) | 11.5 (6 to 23) | 6 (4.5 to 13.5) | 0.195 |
VIS, μg/kg/min | 4.34 (1.94 to 7.31) | 3.55 (1.5 to 6.69) | 6.2 (3.64 to 7.73) | 0.096 |
Proportion with IMV | 69 (93%) | 34 (90%) | 14 (93%) | 1 |
IMV days | 14.5 (6.8 to 25.5) | 15.5 (7 to 25) | 16 (5 to 25.5) | 0.737 |
SOFA max | 10 (7.5 to 12) | 9 (7 to 11) | 10 (8 to 12) | 0.304 |
ICU LOS, days | 17 (8 to 27.5) | 20 (11 to 32) | 17 (6.5 to 26) | 0.368 |
ICU mortality | 14 (19%) | 7 (18.4%) | 2 (13.3%) | 1 |
30-day mortality | 13 (18%) | 7 (18.4%) | 2 (13.3%) | 1 |